As such, we first examined in RPCI-WM1, the expression of 8 stem cell markers whose expression has been shown on lymphoid or myeloid lineage cancers (Fig 4).[24–30] RPCI-WM1 cells were noted to be negative for CD34, 90, 105, 111, 117 and 202b while being positive (>95% of gated cells) for CD110 and CD184 (CXCR4). This evidence concerns the gene CD34 and cancer.